Verrica Pharmaceuticals Inc (NAS:VRCA)
$ 8.56 0.21 (2.51%) Market Cap: 363.12 Mil Enterprise Value: 360.62 Mil PE Ratio: 0 PB Ratio: 237.78 GF Score: 46/100

Verrica Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 17, 2023 / 06:15PM GMT
Release Date Price: $6.32 (+1.94%)
Serge Belanger
Needham & Company - Analyst

Good afternoon. I'm Serge Belanger, one of the senior healthcare analyst at Needham. I'd like to welcome you to the 22nd Annual Needham Healthcare Conference. And for our next session, we have Ted White with us. He's the CEO of Verrica Pharmaceuticals. He's going to tell us about the company and their development program of cantharidin products for molluscum contagiosum. So I'll hand it over to Ted to give us a quick overview of the company.

Ted White
Verrica Pharmaceuticals Inc. - President & CEO

Thank you, Serge, and good afternoon, everyone. As reminder, Verrica, we're a medical dermatology company based in West Chester, Pennsylvania. We have an upcoming potential approval launch of VP-102 for the treatment of molluscum contagiosum, with a PDUFA date coming up on July 23 of this year. In addition, we've also initiated part two of a three-part Phase 2 study for VP-315 for basal cell carcinoma. And just completed the part one of the Phase 2 study where we did see positive results in safety tolerability and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot